Article Archive

BMS-962476

BMS-962476: First in man data

CVD Prevention

2021: ESC Guidelines on cardiovascular disease prevention in clinical practice https://pubmed.ncbi.nlm.nih.gov/34458905/ 2019: ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines https://pubmed.ncbi.nlm.nih.gov/30894318/ 2013: ACC/AHA Lifestyle management to prevent CVD…

ODYSSEY trials at ESC Congress Hotline

ESC Congress 2014: Lipids Hotline: ODYSSEY TRIALS Prof Alberto Zambon, University of Padua, Italy discusses the four ODYSSEY trials with the PCSK9 inhibitor alirocumab presented at ESC Congress Hotline Sunday. Addition of a new investigational agent – Alirocumab – to high doses of statins result…

Lowering LDL-C : at what level would this impact the benefit vs. risk ratio?

Emeritus Research Professor, Institut de recherches cliniques de Montréal (IRCM), Canada Potent inhibitors of pro-protein convertase-subtilisin-kexin-9 (PCSK9) have the capacity to reduce plasma low-density lipoprotein cholesterol (LDL-C) to unprecedentedly low levels, especially if combined with statins. This discovery raises several important questions; how low should…

FH

2021: Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia https://pubmed.ncbi.nlm.nih.gov/33309206/ 2021: Update of the Brazilian Guideline for Familial Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/34709306/ 2019: NICE. Familial hypercholesterolaemia: identification and management https://www.guidelines.co.uk/genetic-conditions/nice-fh-guideline/453843.article 2018: Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018 https://pubmed.ncbi.nlm.nih.gov/30527143/ 2017: Guidelines…

FH detection in primary care: how can we do better?

FH is clearly underdiagnosed and undertreated.1  The question is how to best to address this challenge. FH is one of the most common genetically transmitted conditions, with about 1 in 200-250 people affected.1,2 In the UK, this translates to about 300,000 people affected ; however,…

Low PCSK9 levels in CKD patients on haemodialysis

Serum PCSK9 levels are decreased in patients with chronic kidney disease (CKD) undergoing haemodialysis, thereby implying that PCSK9 plays a similar important role in regulating low-density lipoprotein cholesterol (LDL-C) levels in these patients, as in the general population. Abujrad H, Mayne J, Ruzicka M, Cousins…

Dyslipidaemia management

2021: Lipid Measurements in the Management of Cardiovascular Diseases: NLA Scientific Statement https://www.lipid.org/sites/default/files/files/JACL%201734(3).pdf 2021: Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. https://pubmed.ncbi.nlm.nih.gov/33781847/ 2021: Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease—European Atherosclerosis Society/European…

FH issues in low to middle income regions

Despite the availability of statins, treatment of familial hypercholesterolaemia (FH) is a significant issue with a high unmet need in a middle-income country, according to Dr Dirk Blom of Cape Town, South Africa. As a result, new novel therapies are urgently needed.

Bococizumab

March 30, 2014 1183 – Prevention: Familial Hypercholesterolemia, Novel Therapies and CV Risk Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody against Proprotein Convertase Subtilisin/Kexin Type 9 in Statin-Treated Hypercholesterolemic Subjects: Results from a Randomized, Placebo-Controlled, Dose-Ranging Study (NCT: 01592240) Session 1183-129, 9:45 -…

Does PCSK9 inhibition on top of statin therapy offer the possibility of further reducing plaque burden?

Stephen J Nicholls MBBS PhD South Australian Health and Medical Research Institute, University of Adelaide, Australia Technical advances in arterial wall imaging have enabled the visualization of the full burden of atherosclerotic plaque. When applied in serial imaging studies of anatomically matched arterial segments, it…

The FH enigma: are there other FH-causing genes?

A genetic diagnosis is established in about 80% of patients with FH. The question is what is the genetic basis for FH in the remaining cases. A recent study1 used whole exome sequencing of FH patients negative for LDLR, APOB or PCSK9 mutations, in an…

PCSK9 and plaque: trials

Recent trials have shown that the PCSK9 monoclonal antibodies lower LDL cholesterol by more than 50% on top of statin therapy. There is also evidence that serum PCSK9 is associated with carotid intima-media thickness, a surrogate for atherosclerosis. Lee CJ, Lee YH, Park SW et…

Rising to the Challenge: Implementing Models of Care in FH

Winthrop Professor Gerald F. Watts DSc PhD MD FRACP FRCP, Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital School of Medicine and Pharmacology, University of Western Australia. GPO Box X2213, Perth, WA 6847, Australia; E-mail: [email protected] While several guidelines, mostly based on expert opinion, have…

PCSK9: Opportunities for personalised medicine?

Personalised medicine shifts the focus from a ‘one-size-fits-all’ to patient-centred alternatives. This undoubtedly benefits both patients and healthcare budgets. Such an approach has already been integrated into other disciplines, such as oncology. Is such a strategy also relevant in the management of familial hypercholesterolaemia (FH)?…

What are the current unmet needs?

Despite statins, there are significantly unmet clinical needs in cholesterol lowering treatment. Statin do not effectively treat more than 50% of people with Familial Hypercholesterolaemia (FH) and other patients have intolerable side effects, says Professor Erik Stroes.

Statins and plaque burden

The clinical benefit of LDL cholesterol lowering with statins has been conclusively demonstrated with a wealth of experience from primary and secondary prevention clinical trials.1,2 In addition, imaging studies have shown that statins have a favourable effect on atherosclerosis progression, either stabilising or even decreasing…

Improving the management of the FH patient

Professor Raul Santos from Brazil says that the new therapies which inhibit PCSK9 to significantly reduce low density Lipoprotein Cholesterol (LDL-C) when given in addition to other cholesterol lowering drugs offer a very important advance in reducing cardiovascular risk in people with Familial Hypercholesterolemia (FH).

Do the PCSK9 monoclonal antibodies have neurocognitive adverse effects?

Evolocumab

ACC 2014 March 29th  MENDEL-2: http://www.pcsk9forum.org/mendel-2-2/ DESCARTES: http://www.pcsk9forum.org/descartes-durable-ldl-c-lowering-with-evolocumab/ RUTHERFORD-2: http://www.pcsk9forum.org/acc-2014-rutherford-2-evolocumab-in-heterozygous-fh/ LAPLACE-2: http://www.pcsk9forum.org/acc-2014-latebreaker-laplace-2-evolocumb-effective-in-patients-on-high-and-moderate-intensity-statins/ GAUSS-2: http://www.pcsk9forum.org/acc-2014-latebreaker-gauss-2-evolocumab-addresses-unmet-needs-in-statin-intolerance/